Breast Cancer Research And Treatment

Breast Cancer Research And Treatment

乳腺癌研究和治疗

  • 3区 中科院分区
  • Q2 JCR分区

期刊简介

《Breast Cancer Research And Treatment》是由Springer US出版社于1981年创办的英文国际期刊(ISSN: 0167-6806,E-ISSN: 1573-7217),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为医学-肿瘤学。作为SCIE收录期刊(JCR分区 Q2,中科院 3区),本刊采用OA未开放获取模式(OA占比0.2780...%),以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比93.90%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在328篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Breast Cancer Research And Treatment审稿周期约为 约1月 。该刊近年未被列入国际预警名单,年发文量约328篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 328 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
3区
ONCOLOGY 肿瘤学
3区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
2区
ONCOLOGY 肿瘤学
3区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 142 / 322

56.1%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 135 / 322

58.23%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:6.8 SJR:1.267 SNIP:1.019
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q2 103 / 404

74%

大类:Medicine 小类:Cancer Research Q2 90 / 230

61%

期刊发文

  • Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial

    Author: Xie, Xiao-Feng; Zhang, Qiu-Yi; Huang, Jia-Yi; Chen, Li-Ping; Lan, Xiao-Feng; Bai, Xue; Song, Lin; Xiong, Shui-Ling; Guo, Si-Jia; Du, Cai-Wen

    Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 1, pp. 93-101. DOI: 10.1007/s10549-022-06770-6

  • Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis

    Author: Cao Lu; Yang Yang; Li Lingmei; Huang Qiujuan; Guo Qianru; Qi Lisha; Cao Wenfeng; Niu Yun; Zhang Peisen

    Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 1, pp. 71-82. DOI: 10.1007/s10549-022-06788-w

  • Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population

    Author: Chen, Ruixian; Qi, Yana; Huang, Ya; Liu, Weijing; Yang, Ruoning; Zhao, Xin; Wu, Yunhao; Li, Qintong; Wang, Zhu; Sun, Xin; Wei, Bing; Chen, Jie

    Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 1, pp. 189-200. DOI: 10.1007/s10549-022-06781-3

  • Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis

    Author: Yang, Zhengyan; Xu, Hongyun; Yang, Yupo; Duan, Chaoqun; Zhang, Pai; Wang, Yang; Fu, Kai; Shen, Yonghong; Xu, Marvin Xuejun

    Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 2, pp. 255-267. DOI: 10.1007/s10549-022-06790-2

  • Correlation analysis between shear-wave elastography and pathological profiles in breast cancer

    Author: Li, Junnan; Sun, Bo; Li, Yanbo; Li, Shuang; Wang, Jiahui; Zhu, Ying; Lu, Hong

    Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 2, pp. 269-276. DOI: 10.1007/s10549-022-06804-z

  • Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer

    Author: Wang, Huiling; Sheng, Xiaonan; Yan, Tingting; Xu, Yaqian; Wang, Yaohui; Lin, Yanping; Zhang, Jie; Ye, Yumei; Xu, Shuguang; Zhou, Liheng; Yin, Wenjin; Lu, Jinsong

    Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 2, pp. 343-354. DOI: 10.1007/s10549-022-06791-1

  • Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study

    Author: Xu, Binghe; Li, Wei; Zhang, Qingyuan; Li, Qiao; Wang, Xiaojia; Li, Huiping; Sun, Tao; Yin, Yongmei; Zheng, Hong; Feng, Jifeng; Zhu, Huaqi; Siddiqui, Asna; Macharia, Harrison; Knott, Adam

    Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 3, pp. 503-513. DOI: 10.1007/s10549-022-06775-1

  • Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up

    Author: Gao, Song-lin; Wang, Ding-yuan; Wang, Xi; Zhang, Bo; Du, Feng; Ju, Jie; Yue, Jian; Kang, Yi-kun; Wang, Xue; Xu, Bing-he; Yuan, Peng

    Journal: BREAST CANCER RESEARCH AND TREATMENT. 2023; Vol. 197, Issue 3, pp. 569-582. DOI: 10.1007/s10549-022-06762-6